Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone760-260-8600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$164.25 million
Profitability
Miscellaneous
Employees214
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Retrophin (NASDAQ:RTRX) Frequently Asked Questions
What is Retrophin's stock symbol?
Retrophin trades on the NASDAQ under the ticker symbol "RTRX."
How were Retrophin's earnings last quarter?
Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.27. The biopharmaceutical company had revenue of $44.71 million for the quarter, compared to the consensus estimate of $43.01 million. Retrophin had a negative net margin of 83.94% and a negative return on equity of 47.21%. The firm's revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.25) earnings per share. View Retrophin's Earnings History.
When is Retrophin's next earnings date?
What price target have analysts set for RTRX?
9 analysts have issued 12-month price objectives for Retrophin's stock. Their predictions range from $20.00 to $38.00. On average, they expect Retrophin's share price to reach $29.71 in the next twelve months. This suggests a possible upside of 165.8% from the stock's current price. View Analyst Price Targets for Retrophin.
What is the consensus analysts' recommendation for Retrophin?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.
What are Wall Street analysts saying about Retrophin stock?
Here are some recent quotes from research analysts about Retrophin stock:
- 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (10/9/2019)
- 2. Nomura analysts commented, "in PKU Declined; Frees up ~$65mn. RTRX has declined the option for CNSA-001 after strategic review—this has freed up $65mn in capital (and potential dilution), which may be used for acquisition of new drugs/targets. Recall, RTRX paid $10mn for an option to acquire CNSA-001 program for $65mn in 20% cash/80% stock (at $21.40/sh), plus $25mn in milestone payments, on Jan 4, 2018. New BD a EU PKAN Launch. Stock: FSGS DUPLEX 1H21E (was 2H20E); IgAN 1H22E due to slower- than-expected trial enrollment, steps to speed study completion in progress. Fosmet P3 in PKAN Top Line 3Q19 – Approval Likely Even if Primary Endpoint Misses Stat. Sig. Pending P3 data, RTRX intends to submit both NDA and MAA in 2020. Sensitized primary ep (PKAN-ADL) vs. prior studies (UPDRS) highlights FDA flexibility and breadth of potential to detect clinical benefit. Mgmt." (8/8/2019)
Has Retrophin been receiving favorable news coverage?
Media coverage about RTRX stock has been trending negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Retrophin earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Retrophin.
Who are some of Retrophin's key competitors?
Some companies that are related to Retrophin include Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Prestige Consumer Healthcare (PBH), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Apellis Pharmaceuticals (APLS), Pacira Biosciences (PCRX), Aimmune Therapeutics (AIMT), Tricida (TCDA) and Insmed (INSM).
What other stocks do shareholders of Retrophin own?
Who are Retrophin's key executives?
Retrophin's management team includes the folowing people:
- Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
- Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
- Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
- Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
- Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)
How do I buy shares of Retrophin?
Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Retrophin's stock price today?
One share of RTRX stock can currently be purchased for approximately $11.18.
How big of a company is Retrophin?
Retrophin has a market capitalization of $480.18 million and generates $164.25 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Retrophin employs 214 workers across the globe.View Additional Information About Retrophin.
What is Retrophin's official website?
How can I contact Retrophin?
Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]
MarketBeat Community Rating for Retrophin (NASDAQ RTRX)
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
